Martin Weger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martin Weger has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Olaf Stanger
Atherothrombosis Research Group, Department of Cardiac Surgery, Private Medical University (PMU) Salzburg, Salzburg, Austria
7 shared publicationsAnton Haas
Department of Ophthalmology (M.W., F.J.L., O.S., A.H.), Karl-Franzens University, Graz, Austria
6 shared publicationsOtto Schmut
Department of Ophthalmology, Medical University Graz, Graz, Austria
6 shared publicationsHannes Deutschmann
Department of Ophthalmology (M.W., F.J.L., O.S., A.H.), Karl-Franzens University, Graz, Austria
5 shared publicationsWilfried Renner
Division of Angiology, Department of Internal Medicine (W.R.), Karl-Franzens University, Graz, Austria
5 shared publicationsJürgen Semmelrock
Department of Laboratory Medicine (J.S.), Karl-Franzens University, Graz, Austria
4 shared publications
Latest Publications
- 16 May 2006
- Published by Wiley in Acta Ophthalmologica Scandinavica
- Vol. 84 (3) , 305-308
Angiotensin‐converting enzyme insertion/deletion polymorphism and retinal artery occlusion
An insertion/deletion (I/D) polymorphism of the gene for angiotensin-converting enzyme (ACE) is associated with higher ACE plasma levels and activity. This enzyme is known to play an important role in blood pressure regulation and the ACE I/D gene polymorphism has been suggested as a risk factor for atherosclerotic vascular diseases. The purpose of the present study was to investigate a hypothesized association between the ACE I/D polymorphism and retinal artery occlusion (RAO). A total of 159 patients with RAO and 304 control subjects were enrolled in the present retrospective case-control study. ACE I/D genotypes were determined by polymerase chain reaction. Allelic frequencies and genotype distribution of the ACE I/D polymorphism did not significantly differ between patients and control subjects (ACE DD 25.8% versus 28.0%; p = 0.36). A logistic regression analysis predicted the presence of RAO by arterial hypertension and current smoking status, but not by ACE I/D genotypes. Our data suggest that the ACE I/D polymorphism is not a major risk factor for RAO.
- 16 May 2006
- Published by Wiley in Acta Ophthalmologica Scandinavica
- Vol. 84 (3) , 305-308
Angiotensin‐converting enzyme insertion/deletion polymorphism and retinal artery occlusion
An insertion/deletion (I/D) polymorphism of the gene for angiotensin-converting enzyme (ACE) is associated with higher ACE plasma levels and activity. This enzyme is known to play an important role in blood pressure regulation and the ACE I/D gene polymorphism has been suggested as a risk factor for atherosclerotic vascular diseases. The purpose of the present study was to investigate a hypothesized association between the ACE I/D polymorphism and retinal artery occlusion (RAO). A total of 159 patients with RAO and 304 control subjects were enrolled in the present retrospective case-control study. ACE I/D genotypes were determined by polymerase chain reaction. Allelic frequencies and genotype distribution of the ACE I/D polymorphism did not significantly differ between patients and control subjects (ACE DD 25.8% versus 28.0%; p = 0.36). A logistic regression analysis predicted the presence of RAO by arterial hypertension and current smoking status, but not by ACE I/D genotypes. Our data suggest that the ACE I/D polymorphism is not a major risk factor for RAO.
- 20 August 2003
- Published by Springer Nature in Eye
- Vol. 17 (6) , 731-734
Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion
Purpose Retinal artery occlusion is a common vision-threatening disease. Among other risk factors, coagulopathies leading to a hypercoagulable state have been associated with retinal artery occlusion. Numerous studies have shown that two genetic variants, factor V Leiden and prothrombin 20210A, cause a procoagulant state. However, their role in the pathogenesis of retinal artery occlusion is still unclear. The purpose of the present study was therefore to investigate a possible association between factor V Leiden, prothrombin 20210A, and retinal artery occlusion. Methods In the present retrospective case–control study, we studied 136 patients with retinal artery occlusion and 136 age- and gender-matched control subjects. The presence of factor V Leiden and prothrombin 20210A alleles was determined by polymerase chain reaction. Results The prevalence of heterozygosity for the prothrombin G20210A variant did not significantly differ between patients and controls (three patients vstwo controls, P=0.65). Distribution of factor V Leiden genotypes revealed no significant difference among the two groups (heterozygosity: eight patients vs11 controls, P=0.47). As for other risk factors, arterial hypertension, a history of stroke and myocardial infarction were significantly more frequent in patients than in controls. Conclusion Our data suggest that factor V Leiden and prothrombin 20210A do not play a major role in patients with retinal artery occlusion.
- 20 August 2003
- Published by Springer Nature in Eye
- Vol. 17 (6) , 731-734
Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion
Purpose Retinal artery occlusion is a common vision-threatening disease. Among other risk factors, coagulopathies leading to a hypercoagulable state have been associated with retinal artery occlusion. Numerous studies have shown that two genetic variants, factor V Leiden and prothrombin 20210A, cause a procoagulant state. However, their role in the pathogenesis of retinal artery occlusion is still unclear. The purpose of the present study was therefore to investigate a possible association between factor V Leiden, prothrombin 20210A, and retinal artery occlusion. Methods In the present retrospective case–control study, we studied 136 patients with retinal artery occlusion and 136 age- and gender-matched control subjects. The presence of factor V Leiden and prothrombin 20210A alleles was determined by polymerase chain reaction. Results The prevalence of heterozygosity for the prothrombin G20210A variant did not significantly differ between patients and controls (three patients vstwo controls, P=0.65). Distribution of factor V Leiden genotypes revealed no significant difference among the two groups (heterozygosity: eight patients vs11 controls, P=0.47). As for other risk factors, arterial hypertension, a history of stroke and myocardial infarction were significantly more frequent in patients than in controls. Conclusion Our data suggest that factor V Leiden and prothrombin 20210A do not play a major role in patients with retinal artery occlusion.
- 1 July 2002
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 134 (1) , 57-61
The role of hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with retinal artery occlusion
- 1 July 2002
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 134 (1) , 57-61
The role of hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with retinal artery occlusion
- 1 June 2002
- Published by Elsevier in Ophthalmology
- Vol. 109 (6) , 1105-1109
Hyperhomocyst(e)inemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion
- 1 June 2002
- Published by Elsevier in Ophthalmology
- Vol. 109 (6) , 1105-1109
Hyperhomocyst(e)inemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion
- 1 April 2002
- Published by Elsevier in Ophthalmology
- Vol. 109 (4) , 749-752
Chlamydia pneumoniae seropositivity and the risk of nonarteritic ischemic optic neuropathy
- 1 April 2002
- Published by Elsevier in Ophthalmology
- Vol. 109 (4) , 749-752
Chlamydia pneumoniae seropositivity and the risk of nonarteritic ischemic optic neuropathy
- 21 February 2002
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 240 (4) , 286-290
Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion
Background: Elevated plasma homocyst(e)ine is a major risk factor for venous thrombosis and cardiovascular disease. Homozygosity for the MTHFR C677T mutation and low plasma folate levels increase plasma homocyst(e)ine concentrations. The aim of this retrospective case–control study was to investigate a possible association between hyperhomocyst(e)inemia and central retinal vein occlusion. Methods: Our study included 78 consecutive patients with central retinal vein occlusion and 78 control subjects, matched for age and sex. High-performance liquid chromatography (HPLC) with fluorescence detection was used to determine fasting plasma homocyst(e)ine concentrations. Plasma folate and vitamin B12 levels were determined by immunological assays. Genotyping for the MTHFR C677T mutation was performed by polymerase chain reaction (PCR). Results: Hyperhomocyst(e)inemia was defined by the 95th percentile of plasma homocyst(e)ine concentrations in the control group (=14.83 µmol/l). Thus 16 patients with central retinal vein occlusion were diagnosed as hyperhomocyst(e)inemic, compared with three control subjects (P=0.001). The odds ratio of hyperhomocyst(e)inemia for central retinal vein occlusion was 5.29 (95% CI 1.33–21.13). Mean plasma folate levels were significantly lower in patients than in controls (3.94±1.94 ng/ml vs. 5.69±2.09 ng/ml; PConclusions: Our study suggests that hyperhomocyst(e)inemia, but not the MTHFR C677T mutation, is associated with central retinal vein occlusion.
- 21 February 2002
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 240 (4) , 286-290
Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion
Background: Elevated plasma homocyst(e)ine is a major risk factor for venous thrombosis and cardiovascular disease. Homozygosity for the MTHFR C677T mutation and low plasma folate levels increase plasma homocyst(e)ine concentrations. The aim of this retrospective case–control study was to investigate a possible association between hyperhomocyst(e)inemia and central retinal vein occlusion. Methods: Our study included 78 consecutive patients with central retinal vein occlusion and 78 control subjects, matched for age and sex. High-performance liquid chromatography (HPLC) with fluorescence detection was used to determine fasting plasma homocyst(e)ine concentrations. Plasma folate and vitamin B12 levels were determined by immunological assays. Genotyping for the MTHFR C677T mutation was performed by polymerase chain reaction (PCR). Results: Hyperhomocyst(e)inemia was defined by the 95th percentile of plasma homocyst(e)ine concentrations in the control group (=14.83 µmol/l). Thus 16 patients with central retinal vein occlusion were diagnosed as hyperhomocyst(e)inemic, compared with three control subjects (P=0.001). The odds ratio of hyperhomocyst(e)inemia for central retinal vein occlusion was 5.29 (95% CI 1.33–21.13). Mean plasma folate levels were significantly lower in patients than in controls (3.94±1.94 ng/ml vs. 5.69±2.09 ng/ml; PConclusions: Our study suggests that hyperhomocyst(e)inemia, but not the MTHFR C677T mutation, is associated with central retinal vein occlusion.
- 1 December 2001
- Published by Wolters Kluwer Health in Stroke
- Vol. 32 (12) , 2759-2761
Role of Factor XIII Val34Leu Polymorphism in Retinal Artery Occlusion
Background and Purpose — Factor XIII (FXIII) Val34Leu, a common polymorphism in the gene for factor XIII, has been associated with a lower risk of stroke, myocardial infarction, and deep vein thrombosis. Ineffective fibrin cross-linking has been suggested to be causative. The aim of the present case-control study was to investigate the role of FXIII Val34Leu polymorphism in patients with retinal artery occlusion. Methods — A total of 108 patients with retinal artery occlusion and 313 age- and sex-matched controls were genotyped for the FXIII Val34Leu polymorphism. Factor XIII Val34Leu genotypes were determined by use of allele-specific polymerase chain reaction. Results — Homozygous Leu genotype was found significantly more often in control subjects than in patients with retinal artery occlusion ( P =0.018), with an odds ratio of 0.22 (95% confidence interval 0.07 to 0.74). Distribution of the Val/Val and Val/Leu genotypes did not differ significantly between groups. Conclusions — Because prevalence of homozygous Leu genotype was significantly higher in controls, we conclude that the Leu/Leu genotype is associated with a protective effect against retinal artery occlusion.
- 1 December 2001
- Published by Wolters Kluwer Health in Stroke
- Vol. 32 (12) , 2759-2761
Role of Factor XIII Val34Leu Polymorphism in Retinal Artery Occlusion
Background and Purpose — Factor XIII (FXIII) Val34Leu, a common polymorphism in the gene for factor XIII, has been associated with a lower risk of stroke, myocardial infarction, and deep vein thrombosis. Ineffective fibrin cross-linking has been suggested to be causative. The aim of the present case-control study was to investigate the role of FXIII Val34Leu polymorphism in patients with retinal artery occlusion. Methods — A total of 108 patients with retinal artery occlusion and 313 age- and sex-matched controls were genotyped for the FXIII Val34Leu polymorphism. Factor XIII Val34Leu genotypes were determined by use of allele-specific polymerase chain reaction. Results — Homozygous Leu genotype was found significantly more often in control subjects than in patients with retinal artery occlusion ( P =0.018), with an odds ratio of 0.22 (95% confidence interval 0.07 to 0.74). Distribution of the Val/Val and Val/Leu genotypes did not differ significantly between groups. Conclusions — Because prevalence of homozygous Leu genotype was significantly higher in controls, we conclude that the Leu/Leu genotype is associated with a protective effect against retinal artery occlusion.
- Open Access
- 1 July 2001
- Published by BMJ in British Journal of Ophthalmology
- Vol. 85 (7) , 803-806
Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy
BACKGROUND/AIMS Hyperhomocyst(e)inaemia has been identified as a strong risk factor for stroke, myocardial infarction, and deep vein thrombosis. A point mutation of methylene tetrahydrofolate reductase (MTHFR C677T) has been associated with increased plasma homocyst(e)ine levels. To investigate whether hyperhomocyst(e)inaemia and/or MTHFR C677T mutation are associated with non-arteritic ischaemic optic neuropathy (NAION), a case-control study including 59 consecutive patients with NAION and 59 controls matched for age and sex was performed. METHODS Fasting plasma homocyst(e)ine levels, MTHFR C677T genotypes, and plasma levels of folate and vitamin B-12 were determined. RESULTS Mean plasma homocyst(e)ine levels were significantly higher in patients than in controls (11.8 (SD 5.7) μmol/l v 9.8 (2.5) μmol/l, p = 0.02). The odds ratio for patients with homocyst(e)ine levels exceeding the 95th percentile of control homocyst(e)ine levels was 5.8 (95% CI 1.5–21.4). Mean plasma folate levels were significantly lower in patients than in controls (4.3 (1.7) ng/mlv 5.5 (1.9) ng/ml, p = 0.001), whereas plasma vitamin B-12 levels did not differ significantly. Prevalence of the MTHFR C677T mutation was not significantly increased in patients with NAION compared with controls. CONCLUSION These results suggest that hyperhomocyst(e)inaemia, but not MTHFR C677T mutation is associated with NAION. Determination of plasma homocyst(e)ine levels might be of diagnostic value in patients with NAION.
- 1 July 2001
- Published by BMJ in British Journal of Ophthalmology
- Vol. 85 (7) , 803-806
Open AccessHyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy
BACKGROUND/AIMS Hyperhomocyst(e)inaemia has been identified as a strong risk factor for stroke, myocardial infarction, and deep vein thrombosis. A point mutation of methylene tetrahydrofolate reductase (MTHFR C677T) has been associated with increased plasma homocyst(e)ine levels. To investigate whether hyperhomocyst(e)inaemia and/or MTHFR C677T mutation are associated with non-arteritic ischaemic optic neuropathy (NAION), a case-control study including 59 consecutive patients with NAION and 59 controls matched for age and sex was performed. METHODS Fasting plasma homocyst(e)ine levels, MTHFR C677T genotypes, and plasma levels of folate and vitamin B-12 were determined. RESULTS Mean plasma homocyst(e)ine levels were significantly higher in patients than in controls (11.8 (SD 5.7) μmol/l v 9.8 (2.5) μmol/l, p = 0.02). The odds ratio for patients with homocyst(e)ine levels exceeding the 95th percentile of control homocyst(e)ine levels was 5.8 (95% CI 1.5–21.4). Mean plasma folate levels were significantly lower in patients than in controls (4.3 (1.7) ng/mlv 5.5 (1.9) ng/ml, p = 0.001), whereas plasma vitamin B-12 levels did not differ significantly. Prevalence of the MTHFR C677T mutation was not significantly increased in patients with NAION compared with controls. CONCLUSION These results suggest that hyperhomocyst(e)inaemia, but not MTHFR C677T mutation is associated with NAION. Determination of plasma homocyst(e)ine levels might be of diagnostic value in patients with NAION.